LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article: The potential impact of vaccination on tuberculosis burden in India: A modelling analysis.

    Arinaminpathy, Nimalan / Rade, Kirankumar / Kumar, Ravinder / Joshi, Rajendra P / Rao, Raghuram

    The Indian journal of medical research

    2023  Volume 157, Issue 2&3, Page(s) 119–126

    Abstract: Background & objectives: Vaccination will play an important role in meeting the end tuberculosis (TB) goals. While certain vaccine candidates in advanced stages of clinical trials raise hope for the future availability of new tools, in the immediate ... ...

    Abstract Background & objectives: Vaccination will play an important role in meeting the end tuberculosis (TB) goals. While certain vaccine candidates in advanced stages of clinical trials raise hope for the future availability of new tools, in the immediate term, there is also increasing interest in Bacille Calmette-Guérin revaccination among adults and adolescents as a potential strategy. Here, we sought to estimate the potential epidemiological impact of TB vaccination in India.
    Methods: We developed a deterministic, age-structured, compartmental model of TB in India. Data from the recent national prevalence survey was used to inform epidemiological burden while also incorporating a vulnerable population who may be prioritized for vaccination, the latter consistent with the burden of undernutrition. Using this framework, the potential impact on incidence and mortality of a vaccine with 50 per cent efficacy was estimated, if rolled out in 2023 to cover 50 per cent of the unvaccinated each year. Simulated impacts were compared for disease- vs. infection-preventing vaccines, as well as when prioritizing vulnerable groups (those with undernutrition) rather than the general population. A sensitivity analyses were also conducted with respect to the duration, and efficacy, of vaccine immunity.
    Results: When rolled out in the general population, an infection-preventing vaccine would avert 12 per cent (95% Bayesian credible intervals (Crl): 4.3-28%) of cumulative TB incidence between 2023 and 2030, while a disease-preventing vaccine would avert 29 per cent (95% Crl: 24-34%). Although the vulnerable population accounts for only around 16 per cent of India's population, prioritizing this group for vaccination would achieve almost half the impact of rollout in the general population, in the example of an infection-preventing vaccine. Sensitivity analysis also highlights the importance of the duration and efficacy of vaccine-induced immunity.
    Interpretation & conclusions: These results highlight how even a vaccine with moderate effectiveness (50%) could achieve substantial reductions in TB burden in India, especially when prioritized for the most vulnerable.
    MeSH term(s) Adult ; Adolescent ; Humans ; Bayes Theorem ; Tuberculosis/epidemiology ; Tuberculosis/prevention & control ; Tuberculosis/drug therapy ; Vaccination ; BCG Vaccine/therapeutic use ; India/epidemiology
    Chemical Substances BCG Vaccine
    Language English
    Publishing date 2023-05-18
    Publishing country India
    Document type Journal Article
    ZDB-ID 390883-5
    ISSN 0971-5916 ; 0019-5340
    ISSN 0971-5916 ; 0019-5340
    DOI 10.4103/ijmr.ijmr_328_23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: The potential health and economic impacts of new tuberculosis vaccines under varying delivery strategies in Delhi and Gujarat, India: a modelling study.

    Clark, Rebecca A / Portnoy, Allison / Weerasuriya, Chathika K / Sumner, Tom / Bakker, Roel / Harris, Rebecca C / Rade, Kirankumar / Mattoo, Sanjay Kumar / Tumu, Dheeraj / Menzies, Nicolas A / White, Richard G

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: Background: India has the largest tuberculosis burden globally, but this burden varies nationwide. All-age tuberculosis prevalence in 2021 ranged from 747/100,000 in Delhi to 137/100,000 in Gujarat. Previous modelling has demonstrated the benefits and ... ...

    Abstract Background: India has the largest tuberculosis burden globally, but this burden varies nationwide. All-age tuberculosis prevalence in 2021 ranged from 747/100,000 in Delhi to 137/100,000 in Gujarat. Previous modelling has demonstrated the benefits and costs of introducing novel tuberculosis vaccines in India overall. However, no studies have compared the potential impact of tuberculosis vaccines in regions within India with differing tuberculosis disease and infection prevalence. We used mathematical modelling to investigate how the health and economic impact of two potential tuberculosis vaccines, M72/AS01
    Methods: We applied a compartmental tuberculosis model separately for Delhi (higher disease and infection prevalence) and Gujarat (lower disease and infection prevalence), and projected epidemiological trends to 2050 assuming no new vaccine introduction. We simulated M72/AS01
    Results: M72/AS01
    Discussion: M72/AS01
    Language English
    Publishing date 2023-09-27
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.09.27.23296211
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01

    Clark, Rebecca A / Weerasuriya, Chathika K / Portnoy, Allison / Mukandavire, Christinah / Quaife, Matthew / Bakker, Roel / Scarponi, Danny / Harris, Rebecca C / Rade, Kirankumar / Mattoo, Sanjay Kumar / Tumu, Dheeraj / Menzies, Nicolas A / White, Richard G

    medRxiv : the preprint server for health sciences

    2023  

    Abstract: Background India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01E and BCG-revaccination have recently completed Phase IIb trials and ... ...

    Abstract Background India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01E and BCG-revaccination have recently completed Phase IIb trials and estimates of their population-level impact are needed. We estimated the potential health and economic impact of M72/AS01E and BCG-revaccination in India and investigated the impact of variation in vaccine characteristics and delivery strategies. Methods We developed an age-stratified compartmental tuberculosis transmission model for India calibrated to country-specific epidemiology. We projected baseline epidemiology to 2050 assuming no-new-vaccine introduction, and M72/AS01E and BCG-revaccination scenarios over 2025-2050 exploring uncertainty in product characteristics (vaccine efficacy, mechanism of effect, infection status required for vaccine efficacy, duration of protection) and implementation (achieved vaccine coverage and ages targeted). We estimated reductions in tuberculosis cases and deaths by each scenario compared to no-new-vaccine introduction, as well as costs and cost-effectiveness from health-system and societal perspectives. Results M72/AS01E scenarios were predicted to avert 40% more tuberculosis cases and deaths by 2050 compared to BCG-revaccination scenarios. Cost-effectiveness ratios for M72/AS01E vaccines were around seven times higher than BCG-revaccination, but nearly all scenarios were cost-effective. The estimated average incremental cost was US$190 million for M72/AS01E and US$23 million for BCG-revaccination per year. Sources of uncertainty included whether M72/AS01E was efficacious in uninfected individuals at vaccination, and if BCG-revaccination could prevent disease. Conclusions M72/AS01E and BCG-revaccination could be impactful and cost-effective in India. However, there is great uncertainty in impact, especially given unknowns surrounding mechanism of effect and infection status required for vaccine efficacy. Greater investment in vaccine development and delivery is needed to resolve these unknowns in vaccine product characteristics.
    Language English
    Publishing date 2023-07-10
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.02.24.23286406
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: New tuberculosis vaccines in India: modelling the potential health and economic impacts of adolescent/adult vaccination with M72/AS01

    Clark, Rebecca A / Weerasuriya, Chathika K / Portnoy, Allison / Mukandavire, Christinah / Quaife, Matthew / Bakker, Roel / Scarponi, Danny / Harris, Rebecca C / Rade, Kirankumar / Mattoo, Sanjay Kumar / Tumu, Dheeraj / Menzies, Nicolas A / White, Richard G

    BMC medicine

    2023  Volume 21, Issue 1, Page(s) 288

    Abstract: Background: India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01: Methods: We developed an age-stratified compartmental ... ...

    Abstract Background: India had an estimated 2.9 million tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01
    Methods: We developed an age-stratified compartmental tuberculosis transmission model for India calibrated to country-specific epidemiology. We projected baseline epidemiology to 2050 assuming no-new-vaccine introduction, and M72/AS01
    Results: M72/AS01
    Conclusions: M72/AS01
    MeSH term(s) Adult ; Humans ; Adolescent ; Tuberculosis Vaccines ; BCG Vaccine ; Mycobacterium tuberculosis ; Immunization, Secondary ; Tuberculosis/epidemiology ; Tuberculosis/prevention & control ; Vaccination ; India/epidemiology
    Chemical Substances Tuberculosis Vaccines ; BCG Vaccine
    Language English
    Publishing date 2023-08-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2131669-7
    ISSN 1741-7015 ; 1741-7015
    ISSN (online) 1741-7015
    ISSN 1741-7015
    DOI 10.1186/s12916-023-02992-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: The prevalence of tuberculosis infection in India: A systematic review and meta-analysis.

    Chauhan, Arohi / Parmar, Malik / Dash, Girish Chandra / Solanki, Hardik / Chauhan, Sandeep / Sharma, Jessica / Sahoo, Krushna Chandra / Mahapatra, Pranab / Rao, Raghuram / Kumar, Ravinder / Rade, Kirankumar / Pati, Sanghamitra

    The Indian journal of medical research

    2023  Volume 157, Issue 2&3, Page(s) 135–151

    Abstract: Background & objectives: The National Prevalence Survey of India (2019-2021) estimated 31 per cent tuberculosis infection (TBI) burden among individuals above 15 years of age. However, so far little is known about the TBI burden among the different risk ...

    Abstract Background & objectives: The National Prevalence Survey of India (2019-2021) estimated 31 per cent tuberculosis infection (TBI) burden among individuals above 15 years of age. However, so far little is known about the TBI burden among the different risk groups in India. Thus, this systematic review and meta-analysis, aimed to estimate the prevalence of TBI in India based on geographies, sociodemographic profile, and risk groups.
    Methods: To identify the prevalence of TBI in India, data sources such as MEDLINE, EMBASE, CINAHL, and Scopus were searched for articles reporting data between 2013-2022, irrespective of the language and study setting. TBI data were extracted from 77 publications and pooled prevalence was estimated from the 15 community-based cohort studies. Articles were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines and were sourced using a predefined search strategy from different databases.
    Results: Out of 10,521 records, 77 studies (46 cross-sectional and 31 cohort studies) were included. The pooled TBI prevalence for India based on the community-based cohort studies was estimated as 41 per cent [95% confidence interval (CI) 29.5-52.6%] irrespective of the risk of acquiring it, while the estimation was 36 per cent (95% CI 28-45%) prevalence observed among the general population excluding high-risk groups. Regions with high active TB burden were found to have a high TBI prevalence such as Delhi and Tamil Nadu. An increasing trend of TBI was observed with increasing age in India.
    Interpretation & conclusions: This review demonstrated a high prevalence of TBI in India. The burden of TBI was commensurate with active TB prevalence suggesting possible conversion of TBI to active TB. A high burden was recorded among people residing in the northern and southern regions of the country. Such local epidemiologic variation need to be considered to reprioritize and implement-tailored strategies for managing TBI in India.
    MeSH term(s) Humans ; Prevalence ; India/epidemiology ; Cross-Sectional Studies ; Tuberculosis/epidemiology ; Latent Tuberculosis
    Language English
    Publishing date 2023-05-18
    Publishing country India
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 390883-5
    ISSN 0971-5916 ; 0019-5340
    ISSN 0971-5916 ; 0019-5340
    DOI 10.4103/ijmr.ijmr_382_23
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Correction to: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

    Weerasuriya, Chathika K / Harris, Rebecca C / McQuaid, C Finn / Bozzani, Fiammetta / Ruan, Yunzhou / Li, Renzhong / Li, Tao / Rade, Kirankumar / Rao, Raghuram / Ginsberg, Ann M / Gomez, Gabriela B / White, Richard G

    BMC medicine

    2022  Volume 20, Issue 1, Page(s) 99

    Language English
    Publishing date 2022-03-01
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2131669-7
    ISSN 1741-7015 ; 1741-7015
    ISSN (online) 1741-7015
    ISSN 1741-7015
    DOI 10.1186/s12916-022-02306-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Latent Tuberculosis Infection Diagnosis among Household Contacts in a High Tuberculosis-Burden Area: a Comparison between Transcript Signature and Interferon Gamma Release Assay.

    Kaul, Sheetal / Nair, Vivek / Birla, Shweta / Dhawan, Shikha / Rathore, Sumit / Khanna, Vishal / Lohiya, Sheelu / Ali, Shakir / Mannan, Shamim / Rade, Kirankumar / Malhotra, Pawan / Gupta, Dinesh / Khanna, Ashwani / Mohmmed, Asif

    Microbiology spectrum

    2022  Volume 10, Issue 2, Page(s) e0244521

    Abstract: Diagnosis of latent tuberculosis infection (LTBI) using biomarkers in order to identify the risk of progressing to active TB and therefore predicting a preventive therapy has been the main bottleneck in eradication of tuberculosis. We compared two assays ...

    Abstract Diagnosis of latent tuberculosis infection (LTBI) using biomarkers in order to identify the risk of progressing to active TB and therefore predicting a preventive therapy has been the main bottleneck in eradication of tuberculosis. We compared two assays for the diagnosis of LTBI: transcript signatures and interferon gamma release assay (IGRA), among household contacts (HHCs) in a high tuberculosis-burden population. HHCs of active TB cases were recruited for our study; these were confirmed to be clinically negative for active TB disease. Eighty HHCs were screened by IGRA using QuantiFERON-TB Gold Plus (QFT-Plus) to identify LTBI and uninfected cohorts; further, quantitative levels of transcript for selected six genes (
    MeSH term(s) Humans ; Interferon-gamma Release Tests/methods ; Latent Tuberculosis/diagnosis ; Latent Tuberculosis/epidemiology ; Mass Screening ; Tuberculin Test/methods ; Tuberculosis/diagnosis
    Language English
    Publishing date 2022-04-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2807133-5
    ISSN 2165-0497 ; 2165-0497
    ISSN (online) 2165-0497
    ISSN 2165-0497
    DOI 10.1128/spectrum.02445-21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China.

    Weerasuriya, Chathika K / Harris, Rebecca C / McQuaid, C Finn / Bozzani, Fiammetta / Ruan, Yunzhou / Li, Renzhong / Li, Tao / Rade, Kirankumar / Rao, Raghuram / Ginsberg, Ann M / Gomez, Gabriela B / White, Richard G

    BMC medicine

    2021  Volume 19, Issue 1, Page(s) 60

    Abstract: Background: Despite recent advances through the development pipeline, how novel tuberculosis (TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the epidemiologic impact, cost- ... ...

    Abstract Background: Despite recent advances through the development pipeline, how novel tuberculosis (TB) vaccines might affect rifampicin-resistant and multidrug-resistant tuberculosis (RR/MDR-TB) is unknown. We investigated the epidemiologic impact, cost-effectiveness, and budget impact of hypothetical novel prophylactic prevention of disease TB vaccines on RR/MDR-TB in China and India.
    Methods: We constructed a deterministic, compartmental, age-, drug-resistance- and treatment history-stratified dynamic transmission model of tuberculosis. We introduced novel vaccines from 2027, with post- (PSI) or both pre- and post-infection (P&PI) efficacy, conferring 10 years of protection, with 50% efficacy. We measured vaccine cost-effectiveness over 2027-2050 as USD/DALY averted-against 1-times GDP/capita, and two healthcare opportunity cost-based (HCOC), thresholds. We carried out scenario analyses.
    Results: By 2050, the P&PI vaccine reduced RR/MDR-TB incidence rate by 71% (UI: 69-72) and 72% (UI: 70-74), and the PSI vaccine by 31% (UI: 30-32) and 44% (UI: 42-47) in China and India, respectively. In India, we found both USD 10 P&PI and PSI vaccines cost-effective at the 1-times GDP and upper HCOC thresholds and P&PI vaccines cost-effective at the lower HCOC threshold. In China, both vaccines were cost-effective at the 1-times GDP threshold. P&PI vaccine remained cost-effective at the lower HCOC threshold with 49% probability and PSI vaccines at the upper HCOC threshold with 21% probability. The P&PI vaccine was predicted to avert 0.9 million (UI: 0.8-1.1) and 1.1 million (UI: 0.9-1.4) second-line therapy regimens in China and India between 2027 and 2050, respectively.
    Conclusions: Novel TB vaccination is likely to substantially reduce the future burden of RR/MDR-TB, while averting the need for second-line therapy. Vaccination may be cost-effective depending on vaccine characteristics and setting.
    MeSH term(s) Antitubercular Agents/pharmacology ; Antitubercular Agents/therapeutic use ; China ; Cost-Benefit Analysis/methods ; Humans ; India ; Tuberculosis/epidemiology ; Tuberculosis Vaccines/pharmacology ; Tuberculosis Vaccines/therapeutic use ; Tuberculosis, Multidrug-Resistant/drug therapy
    Chemical Substances Antitubercular Agents ; Tuberculosis Vaccines
    Language English
    Publishing date 2021-02-26
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2131669-7
    ISSN 1741-7015 ; 1741-7015
    ISSN (online) 1741-7015
    ISSN 1741-7015
    DOI 10.1186/s12916-021-01932-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Building a tuberculosis-free world: The Lancet Commission on tuberculosis.

    Reid, Michael J A / Arinaminpathy, Nimalan / Bloom, Amy / Bloom, Barry R / Boehme, Catharina / Chaisson, Richard / Chin, Daniel P / Churchyard, Gavin / Cox, Helen / Ditiu, Lucica / Dybul, Mark / Farrar, Jeremy / Fauci, Anthony S / Fekadu, Endalkachew / Fujiwara, Paula I / Hallett, Timothy B / Hanson, Christy L / Harrington, Mark / Herbert, Nick /
    Hopewell, Philip C / Ikeda, Chieko / Jamison, Dean T / Khan, Aamir J / Koek, Irene / Krishnan, Nalini / Motsoaledi, Aaron / Pai, Madhukar / Raviglione, Mario C / Sharman, Almaz / Small, Peter M / Swaminathan, Soumya / Temesgen, Zelalem / Vassall, Anna / Venkatesan, Nandita / van Weezenbeek, Kitty / Yamey, Gavin / Agins, Bruce D / Alexandru, Sofia / Andrews, Jason R / Beyeler, Naomi / Bivol, Stela / Brigden, Grania / Cattamanchi, Adithya / Cazabon, Danielle / Crudu, Valeriu / Daftary, Amrita / Dewan, Puneet / Doepel, Laurie K / Eisinger, Robert W / Fan, Victoria / Fewer, Sara / Furin, Jennifer / Goldhaber-Fiebert, Jeremy D / Gomez, Gabriela B / Graham, Stephen M / Gupta, Devesh / Kamene, Maureen / Khaparde, Sunil / Mailu, Eunice W / Masini, Enos O / McHugh, Lorrie / Mitchell, Ellen / Moon, Suerie / Osberg, Michael / Pande, Tripti / Prince, Lea / Rade, Kirankumar / Rao, Raghuram / Remme, Michelle / Seddon, James A / Selwyn, Casey / Shete, Priya / Sachdeva, Kuldeep S / Stallworthy, Guy / Vesga, Juan F / Vilc, Valentina / Goosby, Eric P

    Lancet (London, England)

    2019  Volume 393, Issue 10178, Page(s) 1331–1384

    MeSH term(s) Cost of Illness ; Disease Eradication ; Global Health/legislation & jurisprudence ; Global Health/statistics & numerical data ; Goals ; Health Policy ; Health Priorities ; Humans ; Incidence ; Leadership ; Mortality ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/pathogenicity ; Political Systems ; Quality of Health Care/standards ; Quality of Health Care/trends ; Research/economics ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/economics ; Tuberculosis, Pulmonary/epidemiology ; Tuberculosis, Pulmonary/prevention & control ; World Health Organization/economics
    Language English
    Publishing date 2019-03-20
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 3306-6
    ISSN 1474-547X ; 0023-7507 ; 0140-6736
    ISSN (online) 1474-547X
    ISSN 0023-7507 ; 0140-6736
    DOI 10.1016/S0140-6736(19)30024-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top